Quality of life and sexual health in the aging of PCa survivors

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Gacci, Mauro ^a   Baldi, Elisabetta ^b   Tamburrino, Lara ^b   Detti, Beatrice ^c   Livi, Lorenzo ^c   De Nunzio, Cosimo ^d   Tubaro, Andrea ^d   Gravas, Stavros ^e   Carini, Marco ^a   Serni, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ADIPONECTIN; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYTOKINE; ESTROGEN; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; LUTEINIZING HORMONE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TESTOSTERONE;

ABDOMINAL OBESITY; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVOR; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC INFLAMMATION; DRUG MEGADOSE; EORTC QLQ C 30; ERECTILE DYSFUNCTION; EVENING DOSAGE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; INTENSITY MODULATED RADIATION THERAPY; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LONG TERM SURVIVAL; METABOLIC SYNDROME X; NONHUMAN; ORCHIECTOMY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL HEALTH; SHORT FORM 12; STEROIDOGENESIS; UNIVERSITY OF CALIFORNIA LOS ANGELES PROSTATE CANCER INDEX; URINE INCONTINENCE;

EID: 84897483983     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/470592     Document Type: Article

References (174)

1. Sakr W. A., Haas G. P., Cassin B. F., Pontes J. E., Crissman J. D., The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. Journal of Urology 1993 150 2 379 385 2-s2.0-0027244510 (Pubitemid 23215874)
2. Guzzo T. J., Kutikov A., Canter D. J., Tomaszewski J. E., Magerfleish L., VanArsdalen K., Wein A. J., Malkowicz S. B., The clinical and pathological history of prostate cancer progression in men with a prior history of high grade prostatic intraepithelial neoplasia. The Canadian Journal of Urology 2008 15 4 4174 4179 2-s2.0-67649899708
3. Alva A., Hussain M., The changing natural history of metastatic prostate cancer. Cancer Journal 2013 19 1 19 24
4. Boyle P., Maisonneuve P., Napalkov P., Incidence of prostate cancer will double by the year 2030: the argument for. European Urology 1996 29 2 3 9 2-s2.0-0029993793 (Pubitemid 26118350)
5. Grossmann M., Cheung A. S., Zajac J. D., Androgens and prostate cancer, pathogenesis and deprivation therapy. Best Practice and Research. Clinical Endocrinology and Metabolism 2013 27 4 603 616
6. Hellstrom W. J. G., Paduch D., Donatucci C. F., Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review. International Urology and Nephrology 2012 44 1 61 70 2-s2.0-78649741338 10.1007/s11255-010-9879-4
7. Hwang T. I. S., Lo H. C., Tsai T. F., Chiou H. Y., Association among hypogonadism, quality of life and erectile dysfunction in middle-aged and aged male in Taiwan. International Journal of Impotence Research 2007 19 1 69 75 2-s2.0-33846083472 10.1038/sj.ijir.3901480 (Pubitemid 46067351)
8. Xiang Y. Z., Xiong H., Cui Z. L., Jiang S. B., Xia Q. H., Zhao Y., Li G. B., Jin X. B., The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. Journal of Experimental and Clinical Cancer Research 2013 32, article 9 10.1186/1756-9966-32-9
9. Boorjian S. A., Eastham J. A., Graefen M., Guillonneau B., Karnes R. J., Moul J. W., Schaeffer E. M., Stief C., Zorn K. C., A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. European Urology 2012 61 4 664 675 2-s2.0-84857658304 10.1016/j.eururo.2011.11.053
10. Kyrdalen A. E., Dahl A. A., Hernes E., Småstuen M. C., Fosså S. D., A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU International 2013 111 2 221 232
11. Bergman J., Saigal C. S., Kwan L., Litwin M. S., Responsiveness of the University of California-Los Angeles Prostate Cancer Index. Urology 2010 75 6 1418 1423 2-s2.0-77952742885 10.1016/j.urology.2009.04.070
12. Heinzer H., Steuber T., Prostate cancer in the elderly. Urologic Oncology 2009 27 6 668 672 2-s2.0-70350499261 10.1016/j.urolonc.2009.07.015
13. Shafi A. A., Yen A. E., Weigel N. L., Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacology and Therapeutics 2013 140 3 223 238
14. Behre H. M., Bohmeyer J., Nieschlag E., Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clinical Endocrinology 1994 40 3 341 349 2-s2.0-0028358995 (Pubitemid 24194627)
15. Huggins C., Hodges C. V., Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1941 1 293 297 2-s2.0-0036636871
16. Hessels D., Schalken J. A., Recurrent gene in prostate cancer: their clinical implications and uses. Current Urology Reports 2013 14 214 222
17. Carver B. S., Tran J., Chen Z., Carracedo-Perez A., Alimonti A., Nardella C., Gopalan A., Scardino P. T., Cordon-Cardo C., Gerald W., Pandolfi P. P., ETS rearrangements and prostate cancer initiation. Nature 2009 457 7231 E1 2-s2.0-60149091983 10.1038/nature07738
18. Zong Y., Xin L., Goldstein A. S., Lawson D. A., Teitell M. A., Witte O. N., ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proceedings of the National Academy of Sciences of the United States of America 2009 106 30 12465 12470 2-s2.0-68149159298 10.1073/pnas.0905931106
19. Pettersson A., Graff R. E., Bauer S. R., The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiology, Biomarkers and Prevention 2012 21 9 1497 1509
20. McPhaul M. J., Mechanisms of prostate cancer progression to androgen independence. Best Practice and Research. Clinical Endocrinology and Metabolism 2008 22 2 373 388 2-s2.0-42949093654 10.1016/j.beem.2008.02.006 (Pubitemid 351611961)
21. Jagla M., Fève M., Kessler P., Lapouge G., Erdmann E., Serra S., Bergerat J. P., Céraline J., A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007 148 9 4334 4343 2-s2.0-34548057805 10.1210/en.2007-0446 (Pubitemid 47295699)
22. Choucair K., Ejdelman J., Brimo F., PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 2012 12 543 552
23. Sagnak L., Topaloglu H., Ozok U., Ersoy H., Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma. Clinical Genitourinary Cancer 2011 9 2 73 80 2-s2.0-80055061573 10.1016/j.clgc.2011.07. 003
24. Tamburrino L., Salvianti F., Marchiani S., Pinzani P., Nesi G., Serni S., Forti G., Baldi E., Androgen receptor (AR) expression in prostate cancer and progression of the tumor: lessons from cell lines, animal models and human specimens. Steroids 2012 77 10 996 1001 2-s2.0-84856569547 10.1016/j.steroids. 2012.01.008
25. Minner S., Enodien M., Sirma H., Luebke A. M., Krohn A., Mayer P. S., Simon R., Tennstedt P., Müller J., Scholz L., Brase J. C., Liu A. Y., Schlüter H., Pantel K., Schumacher U., Bokemeyer C., Steuber T., Graefen M., Sauter G., Schlomm T., ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clinical Cancer Research 2011 17 18 5878 5888 2-s2.0-80052841071 10.1158/1078-0432.CCR-11-1251
26. Niu Y., Altuwaijri S., Yeh S., Lai K. P., Yu S., Chuang K. H., Huang S. P., Lardy H., Chang C., Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proceedings of the National Academy of Sciences of the United States of America 2008 105 34 12188 12193 2-s2.0-50449094553 10.1073/pnas.0804701105
27. Niu Y., Altuwaijri S., Lai K. P., Wu C. T., Ricke W. A., Messing E. M., Yao J., Yeh S., Chang C., Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2008 105 34 12182 12187 2-s2.0-50449088732 10.1073/pnas.0804700105
28. Mimeault M., Batra S. K., Development of animal models underlining mechanistic connections between prostate inflammation and cancer. World Journal of Clinical Oncology 2013 4 1 4 13 10.5306/wjco.v4.i1.4
29. Bonaccorsi L., Carloni V., Muratori M., Salvadori A., Giannini A., Carini M., Serio M., Forti G., Baldi E., Androgen receptor expression in prostate carcinoma cells suppresses α 6 β 4 integrin-mediated invasive phenotype. Endocrinology 2000 141 9 3172 3182 2-s2.0-0034455571 10.1210/en.141.9.3172 (Pubitemid 32269005)
30. Bonaccorsi L., Carloni V., Muratori M., Formigli L., Zecchi S., Forti G., Baldi E., EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). International Journal of Cancer 2004 112 1 78 86 2-s2.0-4544335595 10.1002/ijc.20362 (Pubitemid 39249494)
31. Bonaccorsi L., Nosi D., Muratori M., Formigli L., Forti G., Baldi E., Altered endocytosis of epidermal growth factor receptor in androgen receptor positve prostate cancer cell lines. Journal of Molecular Endocrinology 2007 38 1-2 51 66 2-s2.0-33847673078 10.1677/jme.1.02155 (Pubitemid 46351592)
32. Cinar B., Koeneman K. S., Edlund M., Prins G. S., Zhau H. E., Chung L. W. K., Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. Cancer Research 2001 61 19 7310 7317 2-s2.0-0035477330 (Pubitemid 32946530)
33. Davis R., Jia D., Cinar B., Sikka S. C., Moparty K., Zhau H. E., Chung L. W., Agrawal K. C., Abdel-Mageed A. B., Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation. Biochemical and Biophysical Research Communications 2003 309 4 937 945 2-s2.0-0141453290 10.1016/j.bbrc.2003.08.096 (Pubitemid 37122620)
34. Guerini V., Sau D., Scaccianoce E., Rusmini P., Ciana P., Maggi A., Martini P. G. V., Katzenellenbogen B. S., Martini L., Motta M., Poletti A., The androgen derivative 5 α -androstane-3 β17 β -diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype. Cancer Research 2005 65 12 5445 5453 2-s2.0-20444457578 10.1158/0008-5472.CAN-04-1941 (Pubitemid 40827358)
35. Niu Y., Chang T. M., Yeh S., Ma W. L., Wang Y. Z., Chang C., Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010 29 25 3593 3604 2-s2.0-77954087303 10.1038/onc.2010.121
36. Zhu M.-L., Kyprianou N., Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. The FASEB Journal 2010 24 3 769 777 2-s2.0-77952308856 10.1096/fj.09-136994
37. Marchiani S., Tamburrino L., Nesi G., Paglierani M., Gelmini S., Orlando C., Maggi M., Forti G., Baldi E., Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation. International Journal of Andrology 2010 33 6 784 793 2-s2.0-78650491839 10.1111/j.1365-2605.2009.01030.x
38. Tian J., Lee S. O., Liang L., Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2′-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. Journal of Biological Chemistry 2012 287 47 39954 39966
39. Kleeberger W., Bova G. S., Nielsen M. E., Herawi M., Chuang A. Y., Epstein J. I., Berman D. M., Roles for the stem cell-associated intermediate filament nestin in prostate cancer migration and metastasis. Cancer Research 2007 67 19 9199 9206 2-s2.0-35148893123 10.1158/0008-5472.CAN-07-0806 (Pubitemid 47535906)
40. Boccon-Gibod L., Hammerer P., Madersbacher S., Mottet N., Prayer-Galetti T., Tunn U., The role of intermittent androgen deprivation in prostate cancer. BJU International 2007 100 4 738 743 2-s2.0-34548443017 10.1111/j.1464-410X. 2007.07053.x (Pubitemid 47360177)
41. Debes J. D., Tindall D. J., Mechanisms of androgen-refractory prostate cancer. The New England Journal of Medicine 2004 351 15 1488 1490 2-s2.0-4744347762 10.1056/NEJMp048178 (Pubitemid 39315314)
42. Thompson I. M. Jr., Goodman P. J., Tangen C. M., Long-term survival of participants in the prostate cancer prevention trial. The New England Journal of Medicine 2013 369 7 603 610
43. Mathew P., Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial. Annals of Oncology 2008 19 2 395 396 2-s2.0-38849121261 10.1093/annonc/mdm568 (Pubitemid 351201727)
44. Morris M. J., Huang D., Kelly W. K., Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. European Urology 2009 56 2 237 244
45. Chuu C. P., Kokontis J. M., Hiipakka R. A., Fukuchi J., Lin H. P., Lin C. Y., Huo C., Su L. C., Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. Journal of Biomedical Science 2011 18 1, article 63 2-s2.0-80052037694 10.1186/1423-0127-18-63
46. Baldi E., Bonaccorsi L., Forti G., Androgen receptor: good guy or bad guy in prostate cancer invasion? Endocrinology 2003 144 5 1653 1655 2-s2.0-0038748334 10.1210/en.2003-0234 (Pubitemid 36543299)
47. Wen S., Niu Y., Lee S. O., Chang C., Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treatment Reviews 2014 40 1 31 40 10.1016/j.ctrv.2013.07.008
48. Hörnberg E., Ylitalo E. B., Crnalic S., Antti H., Stattin P., Widmark A., Bergh A., Wikström P., Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011 6 4 2-s2.0-79955719838 10.1371/journal.pone.0019059 e19059
49. Andersen R. J., Mawji N. R., Wang J., Wang G., Haile S., Myung J.-K., Watt K., Tam T., Yang Y. C., Bañuelos C. A., Williams D. E., McEwan I. J., Wang Y., Sadar M. D., Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010 17 6 535 546 2-s2.0-77953280591 10.1016/j.ccr.2010.04.027
50. Sadar M. D., Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World Journal of Urology 2012 30 3 311 318 2-s2.0-79961150827 10.1007/s00345-011-0745-5
51. Myung J. K., Banuelos C. A., Fernandez J. G., An androgen receptor N-terminal domain antagonist for treating prostate cancer. Journal of Clinical Investigation 2013 123 7 2948 2960
52. Roddam A. W., Allen N. E., Appleby P., Key T. J., Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 2008 100 3 170 183 2-s2.0-39149084101 10.1093/jnci/djm323 (Pubitemid 351480553)
53. Severi G., Morris H. A., MacInnis R. J., English D. R., Tilley W., Hopper J. L., Boyle P., Giles G. G., Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiology Biomarkers and Prevention 2006 15 1 86 91 2-s2.0-33645459812 10.1158/1055-9965.EPI-05-0633
54. Sofikerim M., Eskicorapci S., Ozruç Ö., Özen H., Hormonal predictors of prostate cancer. Urologia Internationalis 2007 79 1 13 18 2-s2.0-34447299663 10.1159/000102906 (Pubitemid 47051811)
55. Corona G., Baldi E., Maggi M., Androgen regulation of prostate cancer: where are we now? Journal of Endocrinological Investigation 2011 34 3 232 243 2-s2.0-79957902488 10.3275/7501
56. Corona G., Gacci M., Baldi E., Mancina R., Forti G., Maggi M., Androgen deprivation therapy in prostate cancer: focusing on sexual side effects. Journal of Sexual Medicine 2012 9 3 887 902 2-s2.0-84857654914 10.1111/j.1743-6109. 2011.02590.x
57. Buvat J., Maggi M., Guay A., Torres L. O., Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. Journal of Sexual Medicine 2013 10 245 284
58. Nishiyama T., Hashimoto Y., Takahashi K., The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research 2004 10 21 7121 7126 2-s2.0-8444231965 10.1158/1078-0432.CCR-04-0913 (Pubitemid 39487695)
59. Page S. T., Lin D. W., Mostaghel E. A., Hess D. L., True L. D., Amory J. K., Nelson P. S., Matsumoto A. M., Bremner W. J., Persistent intraprostatic androgen concentrations after medical castration in healthy men. Journal of Clinical Endocrinology and Metabolism 2006 91 10 3850 3856 2-s2.0-33749550602 10.1210/jc.2006-0968 (Pubitemid 44536854)
60. Titus M. A., Schell M. J., Lih F. B., Tomer K. B., Mohler J. L., Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 2005 11 13 4653 4657 2-s2.0-27644452640 10.1158/1078-0432.CCR-05-0525 (Pubitemid 41557182)
61. Montgomery R. B., Mostaghel E. A., Vessella R., Hess D. L., Kalhorn T. F., Higano C. S., True L. D., Nelson P. S., Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 2008 68 11 4447 4454 2-s2.0-49249119358 10.1158/0008-5472.CAN-08-0249
62. Hofland J., van Weerden W. M., Dits N. F. J., Steenbergen J., van Leenders G. J. L. H., Jenster G., Schröder F. H., de Jong F. H., Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Research 2010 70 3 1256 1264 2-s2.0-76249096762 10.1158/0008-5472.CAN-09- 2092
63. Chang K. H., Li R., Papari-Zareei M., Watumull L., Zhao Y. D., Auchus R. J., Sharifi N., Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2011 108 33 13728 13733 2-s2.0-80051963331 10.1073/pnas.1107898108
64. Fizazi K., Scher H. I., Molina A., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 2012 13 10 983 992
65. Miller L. R., Partin A. W., Chan D. W., Bruzek D. J., Dobs A. S., Epstein J. I., Walsh P. C., Influence of radical prostatectomy on serum hormone levels. Journal of Urology 1998 160 2 449 453 2-s2.0-0032324294 10.1016/S0022-5347(01) 62922-7 (Pubitemid 29476696)
66. Madersbacher S., Schatzl G., Bieglmayer C., Reiter W. J., Gassner C., Berger P., Zidek T., Marberger M., Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology 2002 60 5 869 874 2-s2.0-0036844762 10.1016/S0090-4295(02)01893-9 (Pubitemid 35300357)
67. Lackner J. E., Maerk I., Koller A., Bieglmayer C., Marberger M., Kratzik C., Schatzl G., Serum inhibin not a cause of low testosterone levels in hypogonadal prostate cancer? Urology 2008 72 5 1121 1124 2-s2.0-54449083372 10.1016/j.urology.2008.01.066
68. Olsson M., Ekström L., Schulze J., Kjellman A., Akre O., Rane A., Gustafsson O., Radical prostatectomy: influence on serum and urinary androgen levels. Prostate 2010 70 2 200 205 2-s2.0-73449094875 10.1002/pros.21053
69. Miller L. R., Partin A. W., Chan D. W., Bruzek D. J., Dobs A. S., Epstein J. I., Walsh P. C., Influence of radical prostatectomy on serum hormone levels. Journal of Urology 1998 160 2 449 453 2-s2.0-0032324294 10.1016/S0022-5347(01) 62922-7 (Pubitemid 29476696)
70. Gacci M., Simonato A., Masieri L., Gore J. L., Lanciotti M., Mantella A., Rossetti M. A., Serni S., Varca V., Romagnoli A., Ambruosi C., Venzano F., Esposito M., Montanaro T., Carmignani G., Carini M., Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy. Health and Quality of Life Outcomes 2009 7, article 94 2-s2.0-71049119893 10.1186/1477-7525-7-94
71. Gacci M., Corona G., Apolone A., Lanciotti M., Tosi N., Giancane S., Masieri L., Serni S., Maggi M., Carini M., Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer. Prostate Cancer and Prostatic Diseases 2010 13 2 168 172 2-s2.0-77952550441 10.1038/pcan.2010.4
72. Kirby M. G., Wagg A., Cardozo L., Chapple C., Castro-Diaz D., de Ridder D., Espuna-Pons M., Haab F., Kelleher C., Kólbl H., Milsom I., van Kerrebroeck P., Vierhout M., Salvatore S., Tubaro A., Overactive bladder: is there a link to the metabolic syndrome in men? Neurourology and Urodynamics 2010 29 8 1360 1364 2-s2.0-78349274526 10.1002/nau.20892
73. Kassi E., Pervanidou P., Kaltsas G., Chrousos G., Metabolic syndrome: definitions and controversies. BMC Medicine 2011 9, article 48 2-s2.0-79955562491 10.1186/1741-7015-9-48
74. de Nunzio C., Aronson W., Freedland S. J., Giovannucci E., Parsons J. K., The correlation between metabolic syndrome and prostatic diseases. European Urology 2012 61 3 560 570 2-s2.0-84856381421 10.1016/j.eururo.2011.11.013
75. Gorbachinsky I., Akpinar H., Assimos D. G., Metabolic syndrome and urologic diseases. Reviews in Urology 2010 12 4 e157 e180
76. Hsing A. W., Sakoda L. C., Chua S. Jr., Obesity, metabolic syndrome, and prostate cancer. The American Jurnal of Clinical Nutrition 2007 86 3 s843 857 2-s2.0-40349085518
77. Buschemeyer W. C. III, Freedland S. J., Obesity and prostate cancer: epidemiology and clinical implications. European Urology 2007 52 2 331 343 2-s2.0-34250745251 10.1016/j.eururo.2007.04.069 (Pubitemid 46963472)
78. De Nunzio C., Kramer G., Marberger M., Montironi R., Nelson W., Schröder F., Sciarra A., Tubaro A., The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European Urology 2011 60 1 106 117 2-s2.0-79957957222 10.1016/j.eururo.2011.03. 055
79. Gupta A., Gupta V., Metabolic syndrome: what are the risks for humans? Bioscience Tends 2010 4 5 204 212 2-s2.0-79952276408
80. Duvnjak L., Duvnjak M., The metabolic syndrome-an ongoing story. Journal of Physiology and Pharmacology 2009 60 19 24 2-s2.0-77955899564
81. Ngo T. H., Barnard R. J., Leung P. S., Cohen P., Aronson W. J., Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 2003 144 6 2319 2324 2-s2.0-0038577113 10.1210/en.2003-221028 (Pubitemid 36629883)
82. Huang P. L., A comprehensive definition for metabolic syndrome. Disease Models and Mechanisms 2009 2 5-6 231 237 2-s2.0-67650333178 10.1242/dmm.001180
83. Penna G., Mondaini N., Amuchastegui S., Degli Innocenti S., Carini M., Giubilei G., Fibbi B., Colli E., Maggi M., Adorini L., Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. European Urology 2007 51 2 524 533 2-s2.0-33845570300 10.1016/j.eururo.2006.07.016 (Pubitemid 44937795)
84. Devaraj S., Singh U., Jialal I., Human C-reactive protein and the metabolic syndrome. Current Opinion in Lipidology 2009 20 3 182 189 2-s2.0-67049099210 10.1097/MOL.0b013e32832ac03e
85. Jaggers J. R., Sui X., Hooker S. P., LaMonte M. J., Matthews C. E., Hand G. A., Blair S. N., Metabolic syndrome and risk of cancer mortality in men. European Journal of Cancer 2009 45 10 1831 1838 2-s2.0-66949112574 10.1016/j.ejca.2009.01.031
86. Wallner L. P., Morgenstern H., McGree M. E., Jacobson D. J., St Sauver J. L., Jacobsen S. J., Sarma A. V., The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU International 2011 107 6 929 935 2-s2.0-79952587628 10.1111/j.1464-410X.2010.09703.x
87. Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Willett W. C., Diabetes mellitus and risk of prostate cancer. Cancer Causes and Control 1998 9 1 3 9 2-s2.0-0031985768 10.1023/A:1008822917449 (Pubitemid 28048654)
88. Hamilton R. J., Freedland S. J., Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Current Opinion in Urology 2008 18 3 333 339 2-s2.0-41749107168 10.1097/MOU.0b013e3282f9b3cc (Pubitemid 351489386)
89. Mondul A. M., Clipp S. L., Helzlsouer K. J., Platz E. A., Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes and Control 2010 21 1 61 68 2-s2.0-74149090520 10.1007/s10552-009-9434-8
90. Gacci M., Sebastianelli A., Salvi M., De Nunzio C., Schiavina R., Simonato A., Tubaro A., Mirone V., Carini M., Carmignani G., Role of abdominal obesity for functional outcomes and complications in men treated with radical prostatectomy for prostate cancer: results of the Multicenter Italian Report on Radical Prostatectomy (MIRROR) study. Scandinavian Journal of Urology 2013 10.3109/21681805.2013.803151
91. Laukkanen C., Laukkanen A. J., Laaksonen D. E., Niskanen L., Pukkala E., Hakkarainen A., Salonen J. T., Metabolic syndrome and the risk of prostate cancer in finnish men: a population-based study. Cancer Epidemiology Biomarkers and Prevention 2004 13 10 1646 1650 (Pubitemid 39331887)
92. Håheim L. L., Wisløff T. F., Holme I., Nafstad P., Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. The American Journal of Epidemiology 2006 164 8 769 774 2-s2.0-33749471265 10.1093/aje/kwj284 (Pubitemid 44522081)
93. Martin R. M., Vatten L., Gunnell D., Romundstad P., Nilsen T. I. L., Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes and Control 2009 20 7 1181 1192 2-s2.0-68449101818 10.1007/s10552-009-9319-x
94. Beebe-Dimmer J. L., Nock N. L., Neslund-Dudas C., Rundle A., Bock C. H., Tang D., Jankowski M., Rybicki B. A., Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009 74 1 185 190 2-s2.0-67649213956 10.1016/j.urology.2009.03.013
95. Tande A. J., Platz E. A., Folsom A. R., The metabolic syndrome is associated with reduced risk of prostate cancer. The American Journal of Epidemiology 2006 164 11 1094 1102 2-s2.0-33845227353 10.1093/aje/kwj320 (Pubitemid 44851745)
96. Kheterpal E., Sammon J. D., Diaz M., Bhandari A., Trinh Q. D., Pokala N., Sharma P., Menon M., Agarwal P. K., Effect of metabolic syndrome on pathologic features of prostate cancer. Urologic Oncology 31 7 1054 1059 10.1016/j.urolonc.2011.12.012
97. Litwin M. S., Hays R. D., Fink A., Ganz P. A., Leake B., Brook R. H., The UCLA prostate cancer index: development, reliability, and validity of a health-related quality of life measure. Medical Care 1998 36 7 1002 1012 2-s2.0-0032109544 (Pubitemid 128456439)
98. Gacci M., Livi L., Paiar F., Detti B., Litwin M. S., Bartoletti R., Giubilei G., Cai T., Mariani M., Carini M., Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer Index. Urology 2005 66 2 338 343 2-s2.0-23744513862 10.1016/j.urology.2005.02.027 (Pubitemid 41138094)
99. Hjermstad M. J., Fossa S. D., Bjordal K., Kaasa S., Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. Journal of Clinical Oncology 1995 13 5 1249 1254 2-s2.0-0029033528
100. Ware J. E. Jr., Kosinski M., Keller S. D., A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care 1996 34 3 220 233 2-s2.0-0030096228 (Pubitemid 126433231)
101. Rosen R. C., Riley A., Wagner G., Osterloh I. H., Kirkpatrick J., Mishra A., The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 49 6 822 830 2-s2.0-0030926566 10.1016/S0090-4295(97)00238-0 (Pubitemid 27246947)
102. Mitchell R. E., Shah J. B., Olsson C. A., Benson M. C., McKiernan J. M., Does year of radical prostatectomy independently predict outcome in prostate cancer? Urology 2006 67 2 368 372 2-s2.0-31944438470 10.1016/j.urology.2005.08. 036 (Pubitemid 43189858)
103. Daubenmier J. J., Weidner G., Marlin R., Crutchfield L., Dunn-Emke S., Chi C., Gao B., Carroll P., Ornish D., Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology 2006 67 1 125 130 2-s2.0-30344481144 10.1016/j.urology.2005.07.056 (Pubitemid 43069270)
104. Hoffman K. E., Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity. Seminars in Radiation Oncology 2012 22 4 284 294 10.1016/ j.semradonc.2012.05.005
105. Bian S. X., Hoffman K. E., Management of prostate cancer in elderly men. Seminars in Radiation Oncology 2013 23 3 198 205 10.1016/j.semradonc.2013.01.007
106. Cameron S., Springer C., Fox-Wasylyshyn S., El-Masri M. M., A descriptive study of functions, symptoms, and perceived health state after radiotherapy for prostate cancer. European Journal of Oncology Nursing 2012 16 3 310 314 10.1016/j.ejon.2011.07.007
107. National Center for Health Statistics, Health, United States, 2010: with Special Feature on Death and Dying 2011 Hyattsville, Md, USA National Center for Health Statistics
108. Goineau A., Marchand V., Rigaud J., Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer. Radiation Oncology 2013 8, article 53 10.1186/1748-717X-8-53
109. Niezgoda H. E., Pater J. L., A validation study of the domains of the core EORTC quality of life questionnaire. Quality of Life Research 1993 2 5 319 325 2-s2.0-0027131378 10.1007/BF00449426 (Pubitemid 24011483)
110. Ferrer M., Suárez J. F., Guedea F., Fernández P., Macías V., Mariño A., Hervas A., Herruzo I., Ortiz M. J., Villavicencio H., Craven-Bratle J., Garin O., Aguiló F., Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. International Journal of Radiation Oncology Biology Physics 2008 72 2 421 432 2-s2.0-51449123875 10.1016/j.ijrobp.2007.12.024
111. Sanda M. G., Dunn R. L., Michalski J., Sandler H. M., Northouse L., Hembroff L., Lin X., Greenfield T. K., Litwin M. S., Saigal C. S., Mahadevan A., Klein E., Kibel A., Pisters L. L., Kuban D., Kaplan I., Wood D., Ciezki J., Shah N., Wei J. T., Quality of life and satisfaction with outcome among prostate-cancer survivors. The New England Journal of Medicine 2008 358 12 1250 1261 2-s2.0-40949147326 10.1056/NEJMoa074311 (Pubitemid 351439226)
112. Wei J. T., Dunn R. L., Litwin M. S., Sandler H. M., Sanda M. G., Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000 56 6 899 905 2-s2.0-0033669409 10.1016/S0090-4295(00)00858-X
113. Miller D. C., Sanda M. G., Dunn R. L., Montie J. E., Pimentel H., Sandler H. M., McLaughlin W. P., Wei J. T., Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. Journal of Clinical Oncology 2005 23 12 2772 2780 2-s2.0-18444398952 10.1200/JCO.2005.07.116 (Pubitemid 46179467)
114. Frank S. J., Pisters L. L., Davis J., Lee A. K., Bassett R., Kuban D. A., An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. Journal of Urology 2007 177 6 2151 2156 2-s2.0-34248223102 10.1016/j.juro.2007.01.134 (Pubitemid 46726403)
115. Potosky A. L., Davis W. W., Hoffman R. M., Stanford J. L., Stephenson R. A., Penson D. F., Harlan L. C., Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. Journal of the National Cancer Institute 2004 96 18 1358 1367 2-s2.0-4644287961 10.1093/jnci/djh259 (Pubitemid 39406169)
116. Hoffman R. M., Gilliland F. D., Penson D. F., Stone S. N., Hunt W. C., Potesky A. L., Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 2004 101 9 2011 2019 2-s2.0-7044241080 10.1002/cncr.20608 (Pubitemid 39425377)
117. Smith D. P., King M. T., Egger S., Berry M. P., Stricker P. D., Cozzi P., Ward J., O'Connell D. L., Armstrong B. K., Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 2009 339 b4817 b4828 2-s2.0-84855382780
118. Korfage I. J., Essink-Bot M. L., Borsboom G. J. J. M., Madalinska J. B., Kirkels W. J., Habbema J. D. F., Schröder F. H., de Koning H. J., Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. International Journal of Cancer 2005 116 2 291 296 2-s2.0-22044431995 10.1002/ijc.21043 (Pubitemid 40967268)
119. Hoppe B. S., Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer 2012 118 18 4619 4626 10.1002/cncr.27398
120. Bian S. X., Management of prostate cancer in elderly men. Seminars in Radiation Oncology 2013 23 3 198 205 10.1016/j.semradonc.2013.01.007
121. Nelson C. J., Mulhall J. P., Roth A. J., The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. Journal of Sexual Medicine 2011 8 2 560 566 2-s2.0-79551491185 10.1111/j.1743-6109. 2010.02127.x
122. Helgason Á. R., Adolfsson J., Dickman P., Fredrikson M., Arver S., Steineck G., Waning sexual function-the most important disease-specific distress for patients with prostate cancer. British Journal of Cancer 1996 73 11 1417 1421 2-s2.0-0029993069 (Pubitemid 26175677)
123. Lunenfeld B., Arver S., Moncada I., Rees D. A., Schulte H. M., How to help the aging male? Current approaches to hypogonadism in primary care. The Aging Male 2012 15 4 187 197 10.3109/13685538.2012.729110
124. Incrocci L., Jensen P. T., Pelvic radiotherapy and sexual function in men and women. The Journal of Sexual Medicine 2013 10 supplement 1 53 64 10.1111/jsm.12010
125. Alemozaffar M., Regan M. M., Cooperberg M. R., Wei J. T., Michalski J. M., Sandler H. M., Hembroff L., Sadetsky N., Saigal C. S., Litwin M. S., Klein E., Kibel A. S., Hamstra D. A., Pisters L. L., Kuban D. A., Kaplan I. D., Wood D. P., Ciezki J., Dunn R. L., Carroll P. R., Sanda M. G., Prediction of erectile function following treatment for prostate cancer. Journal of the American Medical Association 2011 306 11 1205 1214 2-s2.0-80053065502 10.1001/jama.2011.1333
126. Karakiewicz P. I., Bhojani N., Neugut A., Shariat S. F., Jeldres C., Graefen M., Perrotte P., Peloquin F., Kattan M. W., The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. Journal of Sexual Medicine 2008 5 4 919 927 2-s2.0-41549154694 10.1111/j.1743-6109.2007.00741.x (Pubitemid 351472202)
127. Lubeck D. P., Litwin M. S., Henning J. M., Stoddard M. L., Flanders S. C., Carroll P. R., Changes in health-related quality of life in the first year after treatment for prostate cancer: results from caPSURE. Urology 1999 53 1 180 186 2-s2.0-0032958078 10.1016/S0090-4295(98)00408-7 (Pubitemid 29016635)
128. Rabbani F., Stapleton A. M. F., Kattan M. W., Wheeler T. M., Scardino P. T., Factors predicting recovery of erections after radical prostatectomy. Journal of Urology 2000 164 6 1929 1934 2-s2.0-0033757905
129. Knight S. J., Latini D. M., Sexual side effects and prostate cancer treatment decisions. Patient information needs and preferences. Cancer Journal 2009 15 1 41 44 2-s2.0-61449219103
130. Carter S., Le J. D., Hu J. C., Anatomic and technical considerations for optimizing recovery of sexual function during robotic-assisted radical prostatectomy. Current Opinion in Urology 2013 23 1 88 94
131. Vora A. A., Dajani D., Lynch J. H., Kowalczyk K. J., Anatomic and technical considerations for optimizing recovery of urinary function during robotic-assisted radical prostatectomy. Current Opinion in Urology 2013 23 1 78 87
132. Bianco F. J. Jr., Scardino P. T., Eastham J. A., Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 2005 66 5 83 94 2-s2.0-25144458366 10.1016/j.urology.2005.06.116 (Pubitemid 41356564)
133. Litwin M. S., Melmed G. Y., Nakazon T., Life after radical prostatectomy: a longitudinal study. Journal of Urology 2001 166 2 587 592 2-s2.0-0034938276 (Pubitemid 32652255)
134. Briganti A., Salonia A., Gallina A., Chun F. K.-H., Karakiewicz P. I., Graefen M., Huland H., Rigatti P., Montorsi F., Management of erectile dysfunction after radical prostatectomy in 2007. World Journal of Urology 2007 25 2 143 148 2-s2.0-34047178355 10.1007/s00345-007-0148-9
135. Gacci M., Ierardi A., Rose A. D., Tazzioli S., Scapaticci E., Filippi S., Maggi M., Nicita G., Carini M., Montorsi F., Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. Journal of Sexual Medicine 2010 7 1 234 243 2-s2.0-74049144034 10.1111/j.1743-6109.2009.01471.x
136. Sacco E., Prayer-Galetti T., Pinto F., Fracalanza S., Betto G., Pagano F., Artibani W., Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU International 2006 97 6 1234 1241 2-s2.0-33745216240 10.1111/j.1464-410X.2006.06185.x (Pubitemid 43907329)
137. Lumen N., Ost P., van Praet C., Developments in external beam radiotherapy for prostate cancer. Urology 2013 82 1 5 10 10.1016/j.urology.2013. 03.043
138. Lisbona A., Averbeck D., Supiot S., Delpon G., Ali D., Vinas F., Diana C., Murariu C., Lagrange J. L., IMRT combined to IGRT: increase of the irradiated volume. Consequences? Cancer Radiothérapie 2010 14 6-7 563 570 2-s2.0-77958166068
139. Crehange G., Mirjolet C., Gauthier M., Martin E., Truc G., Peignaux-Casasnovas K., Azelie C., Bonnetain F., Naudy S., Maingon P., Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiotherapy and Oncology 2012 103 2 244 246 2-s2.0-84860490575 10.1016/j.radonc.2011.10.025
140. Pollack A., Zagars G. K., Smith L. G., Lee J. J., Von Eschenbach A. C., Antolak J. A., Starkschall G., Rosen I., Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology 2000 18 23 3904 3911 2-s2.0-0034554795
141. Zelefsky M. J., Levin E. J., Hunt M., Yamada Y., Shippy A. M., Jackson A., Amols H. I., Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 2008 70 4 1124 1129 2-s2.0-39749192109 10.1016/j.ijrobp.2007.11. 044 (Pubitemid 351296130)
142. Jani A. B., Parikh S. D., Vijayakumar S., Gratzle J., Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 2005 65 6 1157 1162 2-s2.0-20444494949 10.1016/j.urology.2004.12.041 (Pubitemid 40824909)
143. Geinitz H., Zimmermann F. B., Thamm R., Schumertl A., Busch R., Molls M., 3D conformal radiation therapy for prostate cancer in elderly patients. Radiotherapy and Oncology 2005 76 1 27 34 2-s2.0-23244460266 10.1016/j.radonc.2005.06.001 (Pubitemid 41096511)
144. Pinkawa M., Gagel B., Piroth M. D., Fischedick K., Asadpour B., Kehl M., Klotz J., Eble M. J., Erectile dysfunction after external beam radiotherapy for prostate cancer. European Urology 2009 55 1 227 236 2-s2.0-56249102127 10.1016/j.eururo.2008.03.026
145. Pardo Y., Guedea F., Aguiló F., Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. Journal of Clinical Oncology 2010 28 31 4687 4696 10.1200/JCO.2009.25.3245
146. Rice K., Hudak J., Peay K., Elsamanoudi S., Travis J., Lockhart R., Cullen J., Black L., Houge S., Brassell S., Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology 2010 76 5 1231 1238 2-s2.0-78149362565 10.1016/j.urology.2010. 03.087
147. Litwin M. S., Gore J. L., Kwan L., Brandeis J. M., Lee S. P., Withers H. R., Reiter R. E., Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007 109 11 2239 2247 2-s2.0-34249026715 10.1002/cncr.22676 (Pubitemid 46801553)
148. Resnick M. J., Koyama T., Fan K. H., Long-term functional outcomes after treatment for localized prostate cancer. The New England Journal of Medicine 2013 368 5 436 445 10.1056/NEJMoa1209978
149. van der Wielen G. J., Hoogeman M. S., Dohle G. R., van Putten W. L. J., Incrocci L., Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial. International Journal of Radiation Oncology Biology Physics 2008 71 3 795 800 2-s2.0-44449138170 10.1016/j.ijrobp.2007.10.052
150. Mangar S. A., Sydes M. R., Tucker H. L., Coffey J., Sohaib S. A., Gianolini S., Webb S., Khoo V. S., Dearnaley D. P., Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiotherapy and Oncology 2006 80 3 355 362 2-s2.0-33748874677 10.1016/j.radonc.2006.07.037 (Pubitemid 44419432)
151. Wernicke A. G., Valicenti R., DiEva K., Houser C., Pequignot E., Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 2004 60 5 1357 1363 2-s2.0-10044234012 10.1016/j.ijrobp.2004.05.030 (Pubitemid 39601852)
152. Roach M., Winter K., Michalski J. M., Cox J. D., Purdy J. A., Bosch W., Lin X., Shipley W. S., Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. International Journal of Radiation Oncology Biology Physics 2004 60 5 1351 1356 2-s2.0-10044274200 10.1016/j.ijrobp.2004.05.026 (Pubitemid 39601851)
153. Brenner D. J., Hall E. J., Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics 2009 43 5 1095 1101
154. Miralbell R., Roberts S. A., Zubizarreta E., Hendry J. H., Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5, 969 patients in seven international institutional datasets: α/β=1.4 (0.9-2.2). International Journal of Radiation Oncology Biology Physics 2012 82 1 e17 e24 2-s2.0-83955161787 10.1016/j.ijrobp.2010.10. 075
155. Quon H., Cheung C. F., Loblaw D. A., Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics 2012 83 2 617 623 10.1016/j.ijrobp.2011.07.005
156. Namiki S., Ishidoya S., Tochigi T., Kawamura S., Kuwahara M., Terai A., Yoshimura K., Numata I., Satoh M., Saito S., Takai Y., Yamada S., Arai Y., Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Japanese Journal of Clinical Oncology 2006 36 4 224 230 2-s2.0-33745686440 10.1093/jjco/hyl002 (Pubitemid 43997322)
157. Little D. J., Kuban D. A., Levy L. B., Zagars G. K., Pollack A., Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 2003 62 4 707 713 2-s2.0-0141449248 10.1016/S0090-4295(03)00504-1 (Pubitemid 37205010)
158. Kupelian P. A., Reddy C. A., Klein E. A., Willoughby T. R., Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. International Journal of Radiation Oncology Biology Physics 2001 51 4 988 993 2-s2.0-0035889347 10.1016/S0360-3016(01)01730-8 (Pubitemid 33026429)
159. Dieperink K. B., Hansen S., Wagner L., Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. Acta Oncologica 2012 51 6 722 729 10.3109/0284186X.2012.682627
160. Bolla M., Collette L., Blank L., Warde P., Dubois J. B., Mirimanoff R.-O., Storme G., Bernier J., Kuten A., Sternberg C., Mattelaer J., Torecilla J. L., Pfeffer J. R., Cutajar C. L., Zurlo A., Pierart M., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. The Lancet 2002 360 9327 103 108 2-s2.0-0037072063 10.1016/S0140-6736(02)09408-4 (Pubitemid 34786197)
161. Cooperberg M. R., Grossfeld G. D., Lubeck D. P., Carroll P. R., National practice patterns and time trends in androgen ablation for localized prostate cancer. Journal of the National Cancer Institute 2003 95 13 981 989 2-s2.0-0042463650 (Pubitemid 36896715)
162. Wibowo E., Wassersug R. J., The effect of estrogen on the sexual interest of castrated males: implications to prostate cancer patients on androgen-deprivation therapy. Critical Reviews in Oncology/Hematology 2013 87 3 224 238 10.1016/j.critrevonc.2013.01.006
163. Tsujimura A., Role of androgen in the elderly. Problems of androgen deprivation therapy. Clinical Calcium 2013 23 8 1185 1190
164. Fossa S. D., Woehre H., Kurth K.-H., Hetherington J., Bakke H., Rustad D. A., Skanvik R., Influence of urological morbidity on quality of life in patients with prostate cancer. European Urology 1997 31 3 3 8 2-s2.0-0031000557 (Pubitemid 27152013)
165. Dacal K., Sereika S. M., Greenspan S. L., Quality of life in prostate cancer patients taking androgen deprivation therapy. Journal of the American Geriatrics Society 2006 54 1 85 90 2-s2.0-33645113009 10.1111/j.1532-5415.2005. 00567.x
166. Joly F., Alibhai S. M. H., Galica J., Park A., Yi Q.-L., Wagner L., Tannock I. F., Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. Journal of Urology 2006 176 6 2443 2447 2-s2.0-33750505645 10.1016/j.juro.2006.07.151 (Pubitemid 44665959)
167. Lubeck D. P., Grossfeld G. D., Carroll P. R., The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001 58 2 94 99 2-s2.0-0034908783 10.1016/S0090-4295(01)01250-X (Pubitemid 32743420)
168. Holzbeierlein J. M., McLaughlin M. D., Thrasher J. B., Complications of androgen deprivation therapy for prostate cancer. Current Opinion in Urology 2004 14 3 177 183 2-s2.0-2342626087 10.1097/00042307-200405000-00007 (Pubitemid 38582317)
169. Descazeaud A., Chaskalovic J., Debré B., Zerbib M., Peyromaure M., Sexual function after radical prostatectomy does not affect global patient satisfaction. Progres en Urologie 2004 14 6 1177 1180 2-s2.0-12444309303
170. Spry N. A., Kristjanson L., Hooton B., Hayden L., Neerhut G., Gurney H., Corica T., Korbel E., Weinstein S., McCaul K., Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. European Journal of Cancer 2006 42 8 1083 1092 2-s2.0-33746387985 10.1016/j.ejca.2006.01.029 (Pubitemid 44275330)
171. Denham J. W., Wilcox C., Joseph D., Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. The Lancet Oncology 2012 13 12 1260 1270 10.1016/S1470-2045(12)70423-0
172. Schellhammer P. F., An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 2002 3 9 1313 1328 2-s2.0-0036723725 10.1517/14656566.3.9.1313 (Pubitemid 34966046)
173. Stav S. Y., Segal G., The role of bicalutamide in the treatment of prostate cancer. Harefuah 2002 141 4 379 407 2-s2.0-0036546563
174. Iversen P., Tyrrell C. J., Kaisary A. V., Anderson J. B., Baert L., Tammela T., Chamberlain M., Carroll K., Gotting-Smith K., Blackledge G. R. P., Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 51 3 389 396 2-s2.0-0032032068 10.1016/S0090-4295(98)00004-1 (Pubitemid 28136673)